Jonathan Cogen1, Julia Emerson1, Don B Sanders2, Clement Ren3, Michael S Schechter4, Ronald L Gibson1, Wayne Morgan5, Margaret Rosenfeld1. 1. Division of Pulmonary Medicine, Department of Pediatrics, University of Washington, Seattle, Washington. 2. Department of Pediatrics, American Family Children's Hospital, Madison, Wisconsin. 3. Division of Pediatric Pulmonology, University of Rochester, Rochester, New York. 4. Division of Pulmonary Medicine, Department of Pediatrics, Virginia Commonwealth University, Children's Hospital of Richmond at VCU, Richmond, Virginia. 5. Departments of Pediatrics and Physiology, Pediatric Pulmonary Center, University of Arizona, Tucson, Arizona.
Abstract
OBJECTIVE: To identify novel risk factors and corroborate previously identified risk factors for mean annual decline in FEV1% predicted in a large, contemporary, United States cohort of young cystic fibrosis (CF) patients. METHODS: Retrospective observational study of participants in the EPIC Observational Study, who were Pseudomonas-negative and ≤12 years of age at enrollment in 2004-2006. The associations between potential demographic, clinical, and environmental risk factors evaluated during the baseline year and subsequent mean annual decline in FEV1 percent predicted were evaluated using generalized estimating equations. RESULTS: The 946 participants in the current analysis were followed for a mean of 6.2 (SD 1.3) years. Mean annual decline in FEV1% predicted was 1.01% (95%CI 0.85-1.17%). Children with one or no F508del mutations had a significantly smaller annual decline in FEV1 compared to F508del homozygotes. In a multivariable model, risk factors during the baseline year associated with a larger subsequent mean annual lung function decline included female gender, frequent or productive cough, low BMI (<66th percentile, median in the cohort), ≥1 pulmonary exacerbation, high FEV1 (≥115% predicted, in the top quartile), and respiratory culture positive for methicillin-sensitive Staphylococcus aureus, methicillin-resistant S. aureus, or Stenotrophomonas maltophilia. CONCLUSIONS: We have identified a range of risk factors for FEV1 decline in a large cohort of young, CF patients who were Pa negative at enrollment, including novel as well as previously identified characteristics. These results could inform the design of a clinical trial in which rate of FEV1 decline is the primary endpoint and identify high-risk groups that may benefit from closer monitoring.
OBJECTIVE: To identify novel risk factors and corroborate previously identified risk factors for mean annual decline in FEV1% predicted in a large, contemporary, United States cohort of young cystic fibrosis (CF) patients. METHODS: Retrospective observational study of participants in the EPIC Observational Study, who were Pseudomonas-negative and ≤12 years of age at enrollment in 2004-2006. The associations between potential demographic, clinical, and environmental risk factors evaluated during the baseline year and subsequent mean annual decline in FEV1 percent predicted were evaluated using generalized estimating equations. RESULTS: The 946 participants in the current analysis were followed for a mean of 6.2 (SD 1.3) years. Mean annual decline in FEV1% predicted was 1.01% (95%CI 0.85-1.17%). Children with one or no F508del mutations had a significantly smaller annual decline in FEV1 compared to F508del homozygotes. In a multivariable model, risk factors during the baseline year associated with a larger subsequent mean annual lung function decline included female gender, frequent or productive cough, low BMI (<66th percentile, median in the cohort), ≥1 pulmonary exacerbation, high FEV1 (≥115% predicted, in the top quartile), and respiratory culture positive for methicillin-sensitive Staphylococcus aureus, methicillin-resistant S. aureus, or Stenotrophomonas maltophilia. CONCLUSIONS: We have identified a range of risk factors for FEV1 decline in a large cohort of young, CF patients who were Pa negative at enrollment, including novel as well as previously identified characteristics. These results could inform the design of a clinical trial in which rate of FEV1 decline is the primary endpoint and identify high-risk groups that may benefit from closer monitoring.
Authors: Naveen Pillarisetti; Elizabeth Williamson; Barry Linnane; Billy Skoric; Colin F Robertson; Phil Robinson; John Massie; Graham L Hall; Peter Sly; Stephen Stick; Sarath Ranganathan Journal: Am J Respir Crit Care Med Date: 2011-04-14 Impact factor: 21.405
Authors: Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson Journal: J Pediatr Date: 2007-06-22 Impact factor: 4.406
Authors: Margaret Rosenfeld; Julia Emerson; Sharon McNamara; Kelli Joubran; George Retsch-Bogart; Gavin R Graff; Hector H Gutierrez; Jamshed F Kanga; Thomas Lahiri; Blake Noyes; Bonnie Ramsey; Clement L Ren; Michael Schechter; Wayne Morgan; Ronald L Gibson Journal: Pediatr Pulmonol Date: 2010-09
Authors: Zhanhai Li; Michael R Kosorok; Philip M Farrell; Anita Laxova; Susan E H West; Christopher G Green; Jannette Collins; Michael J Rock; Mark L Splaingard Journal: JAMA Date: 2005-02-02 Impact factor: 56.272
Authors: Miriam M Treggiari; Margaret Rosenfeld; Nicole Mayer-Hamblett; George Retsch-Bogart; Ronald L Gibson; Judy Williams; Julia Emerson; Richard A Kronmal; Bonnie W Ramsey Journal: Contemp Clin Trials Date: 2009-01-15 Impact factor: 2.226
Authors: Don B Sanders; Zhanhai Li; Anita Laxova; Michael J Rock; Hara Levy; Jannette Collins; Claude Ferec; Philip M Farrell Journal: Ann Am Thorac Soc Date: 2014-01
Authors: Graham G Willsey; Korin Eckstrom; Annette E LaBauve; Lauren A Hinkel; Kristin Schutz; Robert J Meagher; John J LiPuma; Matthew J Wargo Journal: J Bacteriol Date: 2019-07-10 Impact factor: 3.490
Authors: James M Kidd; Colleen M Sakon; Louise-Marie Oleksiuk; Jeffrey J Cies; Rebecca S Pettit; David P Nicolau; Joseph L Kuti Journal: Antimicrob Agents Chemother Date: 2019-12-20 Impact factor: 5.191
Authors: Sachinkumar B Singh; Amanda J McLearn-Montz; Francesca Milavetz; Levi K Gates; Christopher Fox; Logan T Murry; Ashley Sabus; Harry S Porterfield; Anthony J Fischer Journal: Pediatr Pulmonol Date: 2019-04-22
Authors: Mark L Metersky; Timothy R Aksamit; Alan Barker; Radmila Choate; Charles L Daley; Leigh A Daniels; Angela DiMango; Edward Eden; David Griffith; Margaret Johnson; Michael Knowles; Anne E O'Donnell; Kenneth Olivier; Matthias Salathe; Byron Thomashow; Gregory Tino; Gerard Turino; Kevin L Winthrop; David Mannino Journal: Ann Am Thorac Soc Date: 2018-03
Authors: Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen Journal: Lancet Respir Med Date: 2019-09-27 Impact factor: 30.700